In B16 melanoma and KPC pancreatic cancer mouse models, the addition of an anti-CD93 antibody enhanced the anti-tumor effects mediated by immune checkpoint blockers, such as PD-1 and CTLA-4 monoclonal antibodies, inhibiting tumor growth and prolonging mouse survival [63]. Here, CD93 is linked to melanoma.